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A B S T R A C T
We describe a case of 58-year-old man with septic shock due to Carbapenem-resistant Klebsiella
pneumoniae (CR-Kp) bloodstream infections (BSI) who was successfully treated with a high dose
association of amikacin and imipenem combined with continuous venovenous hemodiaﬁltration
(CVVHDF).
A Klebsiella pneumoniae (Kp) was isolated from the catheter culture and from two blood samples,
drawn from the catheter before removal and from a peripheral vein. The Kp was intermediate to
Amikacin (MIC = 16 mg/ml) and was resistant to all other antibiotics including Imipenem (MIC = 4 mg/
ml), Colistin (MIC = 16 mg/ml) and Tigecycline (MIC = 4 mg/ml) according to the Clinical and Laboratory
Standards Institute (CLSI) published in 2011. PCR ampliﬁcation and sequencing veriﬁed the presence of
blaOXA-48, blaVIM-2, blaCMY-2 and blaSHV-1 genes.
Amikacin was given at a dose of 30 mg/kg (2.5 g) in a 30 min infusion and the dose of imipenem was
increased to 1 g every 6 h despite patient’s altered renal function (Creatinine Clearance = 25 ml/min). To
avoid amikacin nephrotoxicity and to allow the use of high doses of imipenem, continuous venovenous
hemodiaﬁltration (CVVHDF) (blood ﬂow, 200 ml/h; dialysate, 1000 ml/h; ultraﬁltrate, 2000 ml/h) was
initiated 1 h after the start of the amikacin infusion and continued thereafter.
The patient improved hemodynamically and norepinephrine was stopped ﬁve days after
antibiotherapy adaptation.
 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Klebsiella pneumoniae (Kp) producing carbapenemase has
been associated with serious infections and high mortality. The
optimal antimicrobial therapy for Carbapenem-resistant Klebsiella
pneumoniae (CR-Kp) is not well established.* Corresponding author. Tel.: +216 71 391 133; fax: +216 71 391 099.
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We describe a case of a patient with septic shock due to CR-Kp
bloodstream infections (BSI) who was successfully treated with a
high dose association of amikacin and imipenem combined with
continuous venovenous hemodiaﬁltration (CVVHDF).
Our patient was a 58-year-old man, with hypertension and
diabetes mellitus, admitted to the Intensive care unit (ICU) for
septic shock of unknown origin occurring thirteen days after a
coronary artery bypass grafting and mitral valve replacement.
The patient was admitted to ICU, requiring invasive mechanical
ventilation and norepinephrine infusion. Renal function deterio-
rated but creatinine clearance remained higher than 40 ml/min
with preserved urine output. He was febrile (39.5 8C) and he had aCC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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6 days.
The following specimens for culture were obtained: (1) the
distal 4–5 cm of the tip after CVC removal. (2) Two blood samples,
drawn from the catheter and a peripheral vein. (3) Urine culture
and bronchoalveolar lavage.
The absence of sternal instability and data from the computed
tomography (CT) scan made the diagnosis of mediastinitis
improbable.
Transthoracic and transesophageal echocardiography were
then performed and have not shown any valvular abnormality
(vegetations, dysfunction, etc.).
Empirical antibiotic treatment with a combination of Vanco-
mycin (30 mg/kg every 24 h adapted to plasma concentration),
Imipenem (0.5 g every 8 h) and Colistin (3  106 IU every 12 h),
was initiated. The patient’s clinical condition worsened despite
this treatment.
The complementary tests performed to ﬁnd the focus of
infection showed Klebsiella pneumoniae (Kp) isolated from the
catheter culture and from two blood samples, drawn from the
catheter before removal and from a peripheral vein. The Kp was
intermediate to Amikacin (MIC = 16 mg/ml) and was resistant to all
other antibiotics including Imipenem (MIC = 4 mg/ml), Colistin
(MIC = 16 mg/ml) and Tigecycline (MIC = 4 mg/ml) according to the
Clinical and Laboratory Standards Institute (CLSI) published in
2011 [1].
Standard PCR and sequencing were used to identify genes
encoding carbapenemases (blaNDM, blaVIM, blaIMP, blaKPC and
blaOXA-48) [2], extended-spectrum b-lactamases (blaTEM, blaCTX-M
and blaSHV) [3] and plasmid-mediated AmpC (blaCIT, blaFOX, blaMOX,
blaDHA, blaEBC and blaACC) [4]. PCR ampliﬁcation and sequencing
veriﬁed the presence of blaOXA-48, blaVIM-2, blaCMY-2 and blaSHV-1
genes.
Vancomycin and Colistin were stopped and antimicrobial
treatment was therefore changed to amikacin, given at a dose of
30 mg/kg (2.5 g) in a 30 min infusion and the dose of imipenem
was increased to 1 g every 6 h despite patient’s altered renal
function (Creatinine Clearance = 25 ml/min). To avoid amikacin
nephrotoxicity and to allow the use of high doses of imipenem,
continuous venovenous hemodiaﬁltration (CVVHDF) (blood ﬂow,
200 ml/h; dialysate, 1000 ml/h; ultraﬁltrate, 2000 ml/h) was
initiated 1 h after the start of the amikacin infusion and continued
thereafter.
Amikacin was administrated daily with the same regimen as
CVVHDF. By daily monitoring of peak level (obtained 30 min
after the end of the infusion), the dose of amikacin was increased
progressively to reach 60 mg/kg (5 g) resulting in optimal peaks.
The patient improved hemodynamically and norepinephrine
was stopped ﬁve days after antibiotherapy adaptation. Values of
C-reactive protein (CRP), procalcitonin and leukocytes decreased
during treatment and continued to decrease in the following days.
Treatment was tolerated for 14 days without any adverse
effects. The patient was discharged from the intensive care unit
(ICU) four days after the end of therapy. Serum creatinine values
at discharge were similar to those before ICU admission. An
audiometric test was performed and excluded any ototoxicity of
high-dose amikacin in our patient.
Discussion
CR-Kp has become a major hospital pathogen. Infections due to
this organism are associated with high therapeutic failure and
mortality rates of at least 50% [5,6]. The limited number of agents
available for the treatment of CR-Kp presents a tremendous
challenge to clinicians.Colistin, constitutes now a ﬁrst-line regimen for treatment of
infection caused CR-Kp. With the increased use of Colistin,
emergence of Colistin resistance has been reported.
Several recent studies have supported the role of combination
therapy for treating CR-Kp infections. In a cohort of 41 patients
with CR-Kp bacteremia, the use of combination therapy was
associated with improved 28-day mortality [7]. In a review of
published case series and case reports of Treatment of Klebsiella
Pneumoniae Carbapenemase (KPC) infections, Lee and Burgess
report a total of 30 cases received an aminoglycoside, 20% (6/30) of
cases as monotherapy and 80% (24/30) as combination therapy
[8]. There was no signiﬁcant difference in treatment failure
rates between those who received aminoglycoside monotherapy
compared to combination therapy (0% vs. 17%; p = 0.6). Interest-
ingly, all six cases who received aminoglycoside monotherapy
reported success: three cases were treated for BSIs, two cases
were treated for UTIs, and one case was treated for a respiratory
infection. A recent study demonstrated that aminoglycosides,
when active in vitro, were associated with a signiﬁcantly
higher rate of microbiologic clearance of Carbapenem-resistant
K. pneumoniae in the urine compared to polymyxin B or
Tigecycline [9]. Of the patients who received aminoglycoside-
based combination therapy, the most common treatment was
amikacin plus Colistin, followed by aminoglycoside plus a
Carbapenem.
Aminoglycosides are eliminated by the kidneys, and the
potential for renal toxicity has largely limited the use of these
drugs. Renal uptake of amikacin by tubular cells is a saturable
mechanism when drug concentrations exceed 15 mg/ml [10].
In our case the use of high-dose amikacin to treat pathogens
with a MIC of 16 mg/ml would have resulted in drug accumulation
with deleterious effects on renal recovery and in delaying
following injections. Thus, we used CVVHDF to improve extrarenal
clearance of the drug. In our patient, this strategy resulted in
high peak concentrations, with increased antimicrobial efﬁcacy,
and a rapid decrease in drug levels below the threshold of
toxicity.
In conclusion, the use of high dose combination of Imipenem
and amikacin seems to have a survival beneﬁt in Treating
Carbapenem-resistant Klebsiella pneumoniae Bloodstream Infec-
tion. The use of CVVDHF could prevent the development of
nephrotoxicity related to the amikacin accumulation and
increase the antimicrobial activity by allowing daily drug
administration.
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